JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Krystal Biotech Inc

Geschlossen

BrancheGesundheitswesen

147.46 -1.67

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

147.32

Max

149.63

Schlüsselkennzahlen

By Trading Economics

Einkommen

-9.7M

36M

Verkäufe

-3M

88M

KGV

Branchendurchschnitt

35.513

38.156

Gewinnspanne

40.521

Angestellte

275

EBITDA

-5.1M

38M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+33.19% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

4. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-522M

4.3B

Vorheriger Eröffnungskurs

149.13

Vorheriger Schlusskurs

147.46

Nachrichtenstimmung

By Acuity

40%

60%

327 / 375 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Krystal Biotech Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Juli 2025, 17:53 UTC

Wichtige Markttreiber

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25. Juli 2025, 15:58 UTC

Ergebnisse
Wichtige Markttreiber

Aon Shares Rise After 2Q Earnings Beat

25. Juli 2025, 15:08 UTC

Wichtige Markttreiber

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25. Juli 2025, 21:40 UTC

Market Talk

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25. Juli 2025, 21:23 UTC

Market Talk

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25. Juli 2025, 20:40 UTC

Ergebnisse

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25. Juli 2025, 20:10 UTC

Ergebnisse

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. Juli 2025, 19:56 UTC

Ergebnisse

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25. Juli 2025, 19:14 UTC

Market Talk

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25. Juli 2025, 19:10 UTC

Market Talk

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25. Juli 2025, 19:01 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. Juli 2025, 18:45 UTC

Market Talk

Gold Ends Down Week on Lower Note -- Market Talk

25. Juli 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

Sale Could Fetch Around $1B, Sources Say -- WSJ

25. Juli 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH in Talks to Sell Marc Jacobs -- WSJ

25. Juli 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25. Juli 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25. Juli 2025, 17:38 UTC

Wichtige Markttreiber

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25. Juli 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Extends Decline -- Market Talk

25. Juli 2025, 17:13 UTC

Ergebnisse

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25. Juli 2025, 16:46 UTC

Ergebnisse

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25. Juli 2025, 16:45 UTC

Ergebnisse

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25. Juli 2025, 16:27 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. Juli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25. Juli 2025, 16:02 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25. Juli 2025, 15:34 UTC

Ergebnisse

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25. Juli 2025, 15:06 UTC

Market Talk

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25. Juli 2025, 15:05 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25. Juli 2025, 14:45 UTC

Market Talk

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25. Juli 2025, 14:44 UTC

Market Talk

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25. Juli 2025, 14:36 UTC

Market Talk
Ergebnisse

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Peer-Vergleich

Kursveränderung

Krystal Biotech Inc Prognose

Kursziel

By TipRanks

33.19% Vorteil

12-Monats-Prognose

Durchschnitt 199.78 USD  33.19%

Hoch 240 USD

Tief 176 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Krystal Biotech Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

9

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

133.221 / 169.73Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

327 / 375 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.